Measurable residual disease (MRD) that persists after initial therapy is a powerful predictor of relapse and survival in acute lymphoblastic leukemia (ALL). However, the optimal use of this information to influence therapeutic decisions is controversial. Herein, we comprehensively review the role of MRD assessment in adults with ALL, including methods to quantify residual leukemia cells during remission, prognostic impact of MRD across ALL subtypes, and available therapeutic approaches to eradicate MRD. This review presents consensus statements and provides an evidence-based framework for practicing hematologists and oncologists to use MRD information to make rational treatment decisions in adult patients with ALL.
| INTRODUCTION
The vast majority of adults with acute lymphoblastic leukemia (ALL) achieve remission with standard chemotherapy regimens, but many of these patients ultimately relapse and die from leukemia. 1, 2 In these patients, relapse occurs despite achievement of morphologic remission (ie, bone marrow blasts <5%), suggesting that low levels of measurable residual disease (MRD), also called "minimal residual disease," persist in the remission bone marrow ( Figure 1 ). 3 Compared with morphologic assessment alone, sensitive methods of MRD quantification can better estimate the reduction in posttreatment disease burden and provide information about the leukemia biology and treatment response of individual patients. Posttreatment MRD status is a powerful prognostic factor in all subtypes of ALL and, in many studies, supersedes historically relevant prognostic factors, including age, white blood cell count, and cytogenetics. [4] [5] [6] [7] Given the significant impact of MRD on survival outcomes in adults with ALL, many authorities suggest that MRD status can be used to inform postremission strategies, such as allogeneic Herein we review the published data on MRD in ALL, with the goal of developing evidence-based consensus recommendations for the detection and management of MRD in adult patients with ALL.
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Specifically, we review various MRD detection methodologies and discuss how detection and quantification of MRD in various ALL subtypes correlate with outcomes. We also discuss evidence supporting various therapeutic options for patients with MRD-positive remission, including both HSCT and non-HSCT approaches, and provides consensus recommendations to help guide clinician decision-making in this setting. Table 1 . Regardless of the methodology used, for optimal sensitivity MRD assessment should generally be performed on a bone marrow specimen, as levels of detectable MRD may be 1-3 logs lower in the peripheral blood than in the bone marrow. [8] [9] [10] This difference between peripheral blood and bone marrow MRD assessment appears to be most pronounced in patients with B-cell ALL. 10 
| METHODS OF MRD ASSESSMENT
Various
| Flow cytometry
MFC is performed by identifying and tracking aberrant leukemiaassociated immunophenotypes (LAIPs) on leukemic blasts. This can be done either by searching for the diagnostic aberrant LAIP in the remission sample (eg, aberrant expression of myeloid antigens or increased or decreased density of antigens normally expressed on benign B-cell precursors), or by measuring any difference in immunophenotypes from the highly stereotypical normal immunophenotype distribution in the remission sample. 11 In most experienced centers in the United States, the latter "difference from normal" (DfN) approach is now pre- ), although such high levels of sensitivity require input of 2-5 × 10 7 nucleated cells, which is rarely obtainable from remission marrows. PCR for patient-specific IGH and TCR rearrangements may be more specific than BCR-ABL1 monitoring, as BCR-ABL1 can rarely be detected in non-ALL hematopoietic cells. 19 This latter scenario may represent a "CML-like" Ph-positive ALL in which the BCR-ABL1 residual disease status does not necessarily affect prognosis. 20 Despite these potential disadvantages, PCR for BCR-ABL1 is the most common method used for MRD assessment of Ph-positive ALL in US academic centers and appears to be superior to MFC in predicting outcomes in this ALL subtype. or PCR). [22] [23] [24] [25] [26] It is important to note, however, that MFC and PCR can at least theoretically achieve similar levels of sensitivity as NGS if an adequate number of cells or DNA are analyzed, although this is not done in standard practice. In addition to a high degree of sensitivity, NGS is also highly specific for residual disease and may outperform other methods of MRD, particularly PCR. 27 NGS also offers the advantage of being able to track minor subclones, which may be missed with other methodologies; the importance of these subclones in driving relapse is becoming increasingly appreciated in ALL. 28, 29 However, despite the theoretically excellent sensitivity of NGS-based MRD assays (ie, up to 1 leukemia cell per 10 6 nucleated cells), large amounts of cells/DNA from the remission bone marrow are required to achieve this level of sensitivity, which may limit their utility in some scenarios. 
| Consensus recommendations on MRD assessment methodologies
MRD assessment should be performed on bone marrow specimens for optimal sensitivity (particularly for B-cell ALL). PCR for BCR-ABL1 • Very sensitive • Fast (uses consensus primers)
• Potential to track small subclones and clonal evolution 
| T-cell ALL and Ph-negative B-cell ALL in adults
In adults with T-cell ALL or Ph-negative B-cell ALL, the achievement of MRD negativity is predictive for long-term outcomes regardless of whether MFC-or PCR-based assays are used. ).
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These disease subtypes are also more likely to have persistent MRD despite intensive therapy. Other cytogenetic abnormalities including low hypodiploidy and complex cytogenetics (ie, ≥5 chromosomal abnormalities) have also been reported to be associated with poor outcomes, independent of MRD, in some but not all studies. OS rate of 66% despite not undergoing HSCT in first remission. The median OS for patients who achieved CMR by 3 months was 127 versus 38 months for patients who did not achieve CMR (P = .009).
Achievement of CMR was the only variable independently predictive
for OS by multivariate analysis. 57 MRD has also been suggested to predict outcomes in patients with Ph-positive ALL treated with lower-intensity regimens. In a GIMEMA study of younger patients with newly diagnosed Ph-positive ALL treated with dasatinib plus corticosteroids, patients who did not achieve CMR by day 85 were assigned to receive chemotherapy (clofarabine-cyclophosphamide) and/or allogeneic HSCT, depending on patient fitness and donor availability. Patients who achieved CMR received only TKI maintenance. 58 In an interim analysis of this prospective study, the outcomes of patients who achieved CMR were superior to those who did not (30-month disease-free survival rate 75% vs 44%, respectively; P = .06), despite the CMR patients receiving less intensive therapy. • In patients with relapsed or refractory ALL receiving salvage therapy, MRD should be assessed at least at the time of morphologic remission and at the end of treatment, particularly for patients in first salvage in whom this information has greater predictive importance.
| Relapsed or refractory ALL in adults

| THERAPEUTIC APPROACHES FOR PATIENTS WITH PERSISTENT OR RECURRENT MRD
The detection of MRD in patients with ALL serves not only to predict outcomes; it can also inform risk-adapted strategies. For patients with high-risk disease, the goal is to increase the cure rate by intensifying therapies, such as HSCT in first CR, intensification of chemotherapy, or the introduction of novel agents. Conversely, it is also important to identify patients at relatively low risk for relapse, as the goal is to spare these patients from the potential morbidity of these high-intensity treatment approaches. For instance, the treatment-related mortality of
HSCT for adults with ALL may be as high as 30%, with rates of acute and chronic graft-versus-host disease approaching 50%. 66 Utilization of MRD assessment to help avoid allogeneic HSCT in appropriate patients represents a critically important treatment decision. HSCT was associated with a significant benefit in RFS for the whole cohort. 72 However, when patients were stratified according to molecular response, those who achieved a major molecular response after the second cycle of therapy did not seem to benefit from HSCT. A retrospective analysis of patients treated with intensive chemotherapy plus various TKIs who did not undergo HSCT in first remission showed that patients who achieved CMR by 3 months had a 4-year OS rate of 66%.
|
These results were suggestive that a majority of patients with Phpositive ALL who achieve CMR can be cured with chemotherapy and Patients with Ph-positive ALL who achieve CMR within 3 months of therapy may continue to be treated with chemotherapy plus a BCR-ABL1 TKI or undergo HSCT followed by maintenance TKI.
Patients who remain MRD positive after 3 months of therapy should undergo HSCT followed by maintenance TKI. Blinatumomab for 2-4 cycles, with or without concomitant TKI, should be given prior to HSCT, in an attempt to convert to CMR prior to HSCT.
| FUTURE DIRECTIONS AND AREAS OF RESEARCH
While the prognostic impact of MRD assessment is clear across ALL subtypes, many important questions remain about the optimal method of MRD assessment and how this information should be incorporated into risk-adapted therapies. In particular, the deep sensitivity achievable with NGS holds significant promise in the improvement of riskassessment and treatment determination of ALL, although large prospective studies of this technology are needed. Studies are also needed to evaluate the utility of peripheral blood MRD monitoring using these more sensitive NGS-based techniques, including the potential application of circulating cell-free DNA. The complex interaction between molecular and genomic changes in ALL and the prognostic impact of MRD should continue to be explored. As our knowledge of the genomic landscape of ALL evolves, it is likely that optimal assessment of relapse risk, and consequently postremission therapies, will incorporate both pretreatment genomic alterations and posttreatment MRD status.
Finally, prospective MRD-guided studies are needed in order to optimize ALL therapy. The development of novel strategies (eg, monoclonal antibodies alone or in combinations with other antibodies or with chemotherapy; CAR T cells; Bcl-2 inhibitors) is needed to eradicate MRD that persists after initial therapy. Prospective studies should utilize the highest-sensitivity assays available (eg, NGS) and should assess whether such eradication of MRD can obviate the need for HSCT in this setting.
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